Replies to post #79659 on Biotech Values

[Dub Narcotic]

I wonder if Dimebon will be a mixed blessing. Between Dimebon and the acetylcholinesterase inhibitors, it's going to be even harder for a disease modifying drug to show efficacy versus SoC, even if it works, in a one to two year clinical trial. This will be a problem for the drugs in early Phase 2 and under.